These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11315852)

  • 1. Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.
    Morita H; Oki Y; Ito T; Ohishi H; Suzuki S; Nakamura H
    Diabetes Care; 2001 Apr; 24(4):788-9. PubMed ID: 11315852
    [No Abstract]   [Full Text] [Related]  

  • 2. Thiazolidinediones--the new insulin enhancers.
    Jha RJ
    Clin Exp Hypertens; 1999; 21(1-2):157-66. PubMed ID: 10052651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin.
    Willi SM; Kennedy A; Wallace P; Ganaway E; Rogers NL; Garvey WT
    Diabetes; 2002 Oct; 51(10):2895-902. PubMed ID: 12351424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
    N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of troglitazone on insulin sensitivity.
    Henry RR
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
    Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
    Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 8. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
    Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
    Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
    Yamakita T; Ishii T; Mori T; Yoshioka K; Sato T; Tanaka S; Kurimasa H; Fujita K; Fujii S
    Diabetes Res Clin Pract; 1998 Dec; 42(3):205-8. PubMed ID: 9925352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
    Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
    Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Antonucci T; Whitcomb R; McLain R; Lockwood D; Norris RM
    Diabetes Care; 1997 Feb; 20(2):188-93. PubMed ID: 9118772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone in progesterone derivative-induced impairment of glucose tolerance.
    Murao S; Hirata K; Ishida T; Takahara J
    Intern Med; 2000 Apr; 39(4):348-9. PubMed ID: 10801159
    [No Abstract]   [Full Text] [Related]  

  • 13. Troglitazone and related compounds: therapeutic potential beyond diabetes.
    Fujiwara T; Horikoshi H
    Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone and small low-density lipoprotein in type 2 diabetes.
    Hirano T; Yoshino G; Kazumi T
    Ann Intern Med; 1998 Jul; 129(2):162-3. PubMed ID: 9669982
    [No Abstract]   [Full Text] [Related]  

  • 15. Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome.
    Elkind-Hirsch KE; McWilliams RB
    Fertil Steril; 1999 May; 71(5):943-7. PubMed ID: 10231062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone ameliorates insulin resistance in patients with Werner's syndrome.
    Izumino K; Sakamaki H; Ishibashi M; Takino H; Yamasaki H; Yamaguchi Y; Chikuba N; Matsumoto K; Akazawa S; Tokuyama K; Nagataki S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2391-5. PubMed ID: 9253306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 19. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract]   [Full Text] [Related]  

  • 20. New directions in treating insulin resistance.
    Reusch JE
    Hosp Pract (1995); 1995 Sep; 30(9):9-10. PubMed ID: 7559840
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.